vs
LifeStance Health Group, Inc.（LFST）与GeneDx Holdings Corp.（WGS）财务数据对比。点击上方公司名可切换其他公司
LifeStance Health Group, Inc.的季度营收约是GeneDx Holdings Corp.的3.2倍（$382.2M vs $121.0M）。LifeStance Health Group, Inc.净利率更高（3.1% vs -14.6%，领先17.7%）。GeneDx Holdings Corp.同比增速更快（26.5% vs 17.4%）。LifeStance Health Group, Inc.自由现金流更多（$46.6M vs $-7.4M）。过去两年GeneDx Holdings Corp.的营收复合增速更高（39.2% vs 12.8%）
LifeStance Health Group是美国的门诊行为健康服务提供商，支持线下面诊与远程诊疗两种服务模式，业务涵盖心理咨询、精神科诊疗、经颅磁刺激（TMS）以及氯胺酮治疗等。该公司曾多次因劳动违规、客户信息泄露及误导投资者相关问题遭遇诉讼。
GeneDx是一家基因检测企业，2000年由美国国立卫生研究院（NIH）的两位科学家Sherri Bale和John Compton创立，创立初衷是为当时没有商业化检测方案的罕见病及极罕见病患者和家属提供临床诊断服务。公司最初设立于马里兰州及该州蒙哥马利县扶持的生物技术孵化器技术开发中心。
LFST vs WGS — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $382.2M | $121.0M |
| 净利润 | $11.7M | $-17.7M |
| 毛利率 | — | 69.6% |
| 营业利润率 | 4.7% | -11.8% |
| 净利率 | 3.1% | -14.6% |
| 营收同比 | 17.4% | 26.5% |
| 净利润同比 | 264.1% | -424.9% |
| 每股收益（稀释后） | — | $-0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $382.2M | $121.0M | ||
| Q3 25 | $363.8M | $116.7M | ||
| Q2 25 | $345.3M | $102.7M | ||
| Q1 25 | $333.0M | $87.1M | ||
| Q4 24 | $325.5M | $95.6M | ||
| Q3 24 | $312.7M | $76.9M | ||
| Q2 24 | $312.3M | $70.5M | ||
| Q1 24 | $300.4M | $62.4M |
| Q4 25 | $11.7M | $-17.7M | ||
| Q3 25 | $1.1M | $-7.6M | ||
| Q2 25 | $-3.8M | $10.8M | ||
| Q1 25 | $709.0K | $-6.5M | ||
| Q4 24 | $-7.1M | $5.4M | ||
| Q3 24 | $-6.0M | $-8.3M | ||
| Q2 24 | $-23.3M | $-29.2M | ||
| Q1 24 | $-21.1M | $-20.2M |
| Q4 25 | — | 69.6% | ||
| Q3 25 | — | 72.4% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 67.1% | ||
| Q4 24 | — | 69.2% | ||
| Q3 24 | — | 62.2% | ||
| Q2 24 | — | 60.9% | ||
| Q1 24 | — | 59.9% |
| Q4 25 | 4.7% | -11.8% | ||
| Q3 25 | 2.0% | -2.8% | ||
| Q2 25 | -0.9% | 8.7% | ||
| Q1 25 | 0.5% | -5.2% | ||
| Q4 24 | 0.3% | 9.2% | ||
| Q3 24 | 0.0% | -10.1% | ||
| Q2 24 | -5.1% | -15.0% | ||
| Q1 24 | -5.6% | -21.9% |
| Q4 25 | 3.1% | -14.6% | ||
| Q3 25 | 0.3% | -6.5% | ||
| Q2 25 | -1.1% | 10.5% | ||
| Q1 25 | 0.2% | -7.5% | ||
| Q4 24 | -2.2% | 5.7% | ||
| Q3 24 | -1.9% | -10.8% | ||
| Q2 24 | -7.5% | -41.4% | ||
| Q1 24 | -7.0% | -32.4% |
| Q4 25 | — | $-0.59 | ||
| Q3 25 | — | $-0.27 | ||
| Q2 25 | — | $0.36 | ||
| Q1 25 | — | $-0.23 | ||
| Q4 24 | — | $0.25 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | — | $-1.10 | ||
| Q1 24 | — | $-0.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $248.6M | $171.3M |
| 总债务越低越好 | $282.8M | $54.5M |
| 股东权益账面价值 | $1.5B | $308.2M |
| 总资产 | $2.2B | $523.7M |
| 负债/权益比越低杠杆越低 | 0.19× | 0.18× |
8季度趋势，按日历期对齐
| Q4 25 | $248.6M | $171.3M | ||
| Q3 25 | $203.9M | $155.1M | ||
| Q2 25 | $188.9M | $134.6M | ||
| Q1 25 | $134.3M | $159.2M | ||
| Q4 24 | $154.6M | $141.2M | ||
| Q3 24 | $102.6M | $116.5M | ||
| Q2 24 | $87.0M | $106.9M | ||
| Q1 24 | $49.5M | $112.9M |
| Q4 25 | $282.8M | $54.5M | ||
| Q3 25 | $284.6M | $54.8M | ||
| Q2 25 | $286.4M | $55.1M | ||
| Q1 25 | $288.2M | $55.5M | ||
| Q4 24 | $290.0M | $55.8M | ||
| Q3 24 | $287.3M | $56.1M | ||
| Q2 24 | $288.0M | $56.3M | ||
| Q1 24 | $288.8M | $56.3M |
| Q4 25 | $1.5B | $308.2M | ||
| Q3 25 | $1.5B | $292.3M | ||
| Q2 25 | $1.5B | $277.1M | ||
| Q1 25 | $1.5B | $257.4M | ||
| Q4 24 | $1.4B | $245.2M | ||
| Q3 24 | $1.4B | $204.5M | ||
| Q2 24 | $1.4B | $194.0M | ||
| Q1 24 | $1.4B | $207.2M |
| Q4 25 | $2.2B | $523.7M | ||
| Q3 25 | $2.1B | $493.9M | ||
| Q2 25 | $2.1B | $463.9M | ||
| Q1 25 | $2.1B | $446.4M | ||
| Q4 24 | $2.1B | $419.4M | ||
| Q3 24 | $2.1B | $408.8M | ||
| Q2 24 | $2.1B | $389.1M | ||
| Q1 24 | $2.1B | $394.5M |
| Q4 25 | 0.19× | 0.18× | ||
| Q3 25 | 0.19× | 0.19× | ||
| Q2 25 | 0.19× | 0.20× | ||
| Q1 25 | 0.20× | 0.22× | ||
| Q4 24 | 0.20× | 0.23× | ||
| Q3 24 | 0.20× | 0.27× | ||
| Q2 24 | 0.20× | 0.29× | ||
| Q1 24 | 0.20× | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $57.6M | $-3.1M |
| 自由现金流经营现金流 - 资本支出 | $46.6M | $-7.4M |
| 自由现金流率自由现金流/营收 | 12.2% | -6.1% |
| 资本支出强度资本支出/营收 | 2.9% | 3.6% |
| 现金转化率经营现金流/净利润 | 4.93× | — |
| 过去12个月自由现金流最近4个季度 | $110.0M | $14.3M |
8季度趋势，按日历期对齐
| Q4 25 | $57.6M | $-3.1M | ||
| Q3 25 | $27.3M | $15.8M | ||
| Q2 25 | $64.4M | $10.4M | ||
| Q1 25 | $-3.1M | $10.2M | ||
| Q4 24 | $62.3M | $-3.2M | ||
| Q3 24 | $22.7M | $-4.4M | ||
| Q2 24 | $44.1M | $-4.5M | ||
| Q1 24 | $-21.8M | $-16.4M |
| Q4 25 | $46.6M | $-7.4M | ||
| Q3 25 | $17.0M | $9.6M | ||
| Q2 25 | $56.6M | $8.1M | ||
| Q1 25 | $-10.3M | $4.1M | ||
| Q4 24 | $56.0M | $-6.2M | ||
| Q3 24 | $17.7M | $-5.0M | ||
| Q2 24 | $39.0M | $-5.9M | ||
| Q1 24 | $-26.9M | $-16.9M |
| Q4 25 | 12.2% | -6.1% | ||
| Q3 25 | 4.7% | 8.2% | ||
| Q2 25 | 16.4% | 7.8% | ||
| Q1 25 | -3.1% | 4.7% | ||
| Q4 24 | 17.2% | -6.5% | ||
| Q3 24 | 5.7% | -6.6% | ||
| Q2 24 | 12.5% | -8.3% | ||
| Q1 24 | -9.0% | -27.0% |
| Q4 25 | 2.9% | 3.6% | ||
| Q3 25 | 2.8% | 5.3% | ||
| Q2 25 | 2.2% | 2.3% | ||
| Q1 25 | 2.2% | 7.0% | ||
| Q4 24 | 1.9% | 3.2% | ||
| Q3 24 | 1.6% | 0.8% | ||
| Q2 24 | 1.6% | 1.9% | ||
| Q1 24 | 1.7% | 0.7% |
| Q4 25 | 4.93× | — | ||
| Q3 25 | 25.34× | — | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | -4.36× | — | ||
| Q4 24 | — | -0.59× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LFST
暂无分部数据
WGS
| Diagnostic Test Third Party Insurance | $101.1M | 84% |
| Diagnostic Test Institutional Customers | $15.5M | 13% |
| Other | $3.4M | 3% |
